Streetbeat News

Earnings

MRNA

Moderna has reaffirmed its 2024 revenue forecast for its respiratory franchise at approximately $4B, slightly below the consensus estimate of $4.21B. The company also expects around $0.3B in net sales for the first half of 2024, highlighting the seasonal nature of the respiratory business.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:37 am

VNT

Vontier forecasts FY24 sales to be between $3.040B and $3.100B, aligning closely with the $3.096B estimate. The company also reiterated its adjusted EPS guidance of $3.00 to $3.15, which is in line with the $3.12 estimate. Key highlights include a core sales growth of 4 to 6%, an adjusted operating profit margin expansion of 80 to 110 basis points year-over-year, and an adjusted free cash flow conversion of approximately 90 to 100%.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:37 am

UTZ

Utz Brands has reaffirmed its financial outlook for FY24, projecting an organic net sales growth of approximately 3% or better and an adjusted EBITDA growth of 5% to 8%.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:36 am

RXO

RXO reported Q1 adjusted losses of $(0.03) per share, beating the $(0.04) estimate, but its sales of $913M missed the $929.48M estimate, marking a 9.60% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:35 am

TFX

Teleflex has updated its FY24 adjusted EPS guidance, raising the lower end from $13.55 to $13.60, while maintaining the upper end at $13.95, compared to the market estimate of $13.73.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:35 am

CVNA

Carvana shares are trading higher following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:34 am

Z

ZG

Zillow's stock price has decreased following the announcement of its Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:34 am

BFLY

Butterfly Network shares surged following the announcement of their Q1 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:34 am

MRNA

Moderna reported Q1 2024 GAAP EPS of $(3.07), surpassing the $(3.55) estimate, with sales of $167M also beating the $97.501M forecast. Despite beating estimates, this represents a significant decrease from the previous year's earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:34 am

ENVX

Enovix shares are trading higher following the announcement of mixed Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:34 am